INCB14943
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205493

CAS#: 914471-09-3 (INCB14943)

Description: INCB14943, also known as INCB024360-analog, IDO5L and IDO-IN-2 with CAS#914471-09-3, is a potent and orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase (IDO1) with potential immunomodulating and antineoplastic activities. INCB024360-analog is a potent (HeLa IC50=19 nM) competitive inhibitor of IDO. Testing of INCB024360-analog in mice demonstrated pharmacodynamic inhibition of IDO, as measured by decreased kynurenine levels (>50%) in plasma and dose dependent efficacy. Note: MedKoo CAT#206461, INCB024360 has CAS#1204669-58-8 (http://www.medkoo.com/products/6778)


Price and Availability

Size Price Shipping out time Quantity
50mg USD 150 Same day
100mg USD 250 Same day
200mg USD 450 Same day
500mg USD 650 Same day
1g USD 1050 Same day
2g USD 1850 Same day
5g USD 3850 Same day
Inquire bulk and customized quantity

Pricing updated 2020-06-03. Prices are subject to change without notice.

INCB14943, purity > 98%, is in stock. The same day shipping out after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 205493
Name: INCB14943
CAS#: 914471-09-3 (INCB14943)
Chemical Formula: C9H7ClFN5O2
Exact Mass: 271.02723
Molecular Weight: 271.63
Elemental Analysis: C, 39.79; H, 2.60; Cl, 13.05; F, 6.99; N, 25.78; O, 11.78


Related CAS #: 1204669-58-8 (INCB024360)   1204669-37-3 (INCB024360)   914471-09-3 (INCB14943)    

Synonym: INCB14943; INCB-14943; INCB 14943; INCB024360-analog; INCB24360-analog; Epacadostat-analog. IDO-IN-2; IDO5L;

IUPAC/Chemical Name: 4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide

InChi Key: HGXSLPIXNPASGZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C9H7ClFN5O2/c10-5-3-4(1-2-6(5)11)13-9(14-17)7-8(12)16-18-15-7/h1-3,17H,(H2,12,16)(H,13,14)

SMILES Code: O/N=C(C1=NON=C1N)/NC2=CC=C(F)C(Cl)=C2


Technical Data

Appearance:
white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (SDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
Stock solution may be formulated in DMSO, DMA, etc.

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


Additional Information

INCB024360-Analog is structurally related to Epacadostat (INCB024360). Before middle of 2015, some database (e.g, pubchem CID#11978742) mistakenly listed INCB024360 structure as CAS#914471-09-3, many reagent suppliers included MedKoo used pubchem's structure and sold CAS#914471-09-3 as INCB024360. By middle of 2015, J. Med. Chem (Dounay AB, et al, and Röhrig UF et al ), Sci-Finder and other database (such as ChemIDplus) published the chemical structure of INCB024360, which has CAS#1204669-58-8. Based on the above information, MedKoo decided to re-name Cat#205493, CAS#914471-09-3 as INCB024360-Analog. However, as of August 20, 2015, there are still many reagent companies to sell the wrong INCB024360, which structure was actually CAS#914471-09-3 (or INCB024360-Analog). Customer can email or call MedKoo to clarify the structure issue related to INCB024360. (last updated: 12/21/2015).
* * *
INCB024360-Analog was first reported in J. Med. Chem. 2009, 52, 7364–7367.
http://www.ncbi.nlm.nih.gov/pubmed/19507862
* * * **
Note: Structure of INCB14943 was from https://dx.doi.org/10.1021/acsmedchemlett.9b00572


References

1: Song X, Sun P, Wang J, Guo W, Wang Y, Meng LH, Liu H. Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors. Eur J Med Chem. 2020 Jan 11;189:112059. doi: 10.1016/j.ejmech.2020.112059. [Epub ahead of print] PubMed PMID: 31981851.

2: Peng YH, Liao FY, Tseng CT, Kuppusamy R, Li AS, Chen CH, Fan YS, Wang SY, Wu MH, Hsueh CC, Chang JY, Lee LC, Shih C, Shia KS, Yeh TK, Hung MS, Kuo CC, Song JS, Wu S, Ueng SH. Unique sulfur-aromatic interactions contribute to the binding of potent imidazothiazole indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2020 Jan 21. doi: 10.1021/acs.jmedchem.9b01549. [Epub ahead of print] PubMed PMID: 31961685.

3: Devaraja K. Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma. Pharmaceut Med. 2019 Aug;33(4):269-289. doi: 10.1007/s40290-019-00288-x. PubMed PMID: 31933185.

4: Chu CE, Porten SP, Grossfeld GD, Meng MV. Role of Indoleamine-2,3-Dioxygenase Inhibitors in Salvage Therapy for Non-Muscle Invasive Bladder Cancer. Urol Clin North Am. 2020 Feb;47(1):111-118. doi: 10.1016/j.ucl.2019.09.013. Review. PubMed PMID: 31757294.

5: Röhrig UF, Reynaud A, Majjigapu SR, Vogel P, Pojer F, Zoete V. Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1). J Med Chem. 2019 Oct 10;62(19):8784-8795. doi: 10.1021/acs.jmedchem.9b00942. Epub 2019 Sep 26. PubMed PMID: 31525930.

6: Du Q, Feng X, Wang Y, Xu X, Zhang Y, Qu X, Li Z, Bian J. Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer. Eur J Med Chem. 2019 Nov 15;182:111629. doi: 10.1016/j.ejmech.2019.111629. Epub 2019 Aug 18. PubMed PMID: 31445231.

7: Venkateswaran N, Lafita-Navarro MC, Hao YH, Kilgore JA, Perez-Castro L, Braverman J, Borenstein-Auerbach N, Kim M, Lesner NP, Mishra P, Brabletz T, Shay JW, DeBerardinis RJ, Williams NS, Yilmaz OH, Conacci-Sorrell M. MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer. Genes Dev. 2019 Sep 1;33(17-18):1236-1251. doi: 10.1101/gad.327056.119. Epub 2019 Aug 15. PubMed PMID: 31416966; PubMed Central PMCID: PMC6719621.

8: Mathsyaraja H, Freie B, Cheng PF, Babaeva E, Catchpole JT, Janssens D, Henikoff S, Eisenman RN. Max deletion destabilizes MYC protein and abrogates Eµ-Myc lymphomagenesis. Genes Dev. 2019 Sep 1;33(17-18):1252-1264. doi: 10.1101/gad.325878.119. Epub 2019 Aug 8. PubMed PMID: 31395740; PubMed Central PMCID: PMC6719623.

9: Feng X, Shen P, Wang Y, Li Z, Bian J. Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO. Biochem Pharmacol. 2019 Oct;168:214-223. doi: 10.1016/j.bcp.2019.07.011. Epub 2019 Jul 12. PubMed PMID: 31306643.

10: Chen S, Guo W, Liu X, Sun P, Wang Y, Ding C, Meng L, Zhang A. Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors. Eur J Med Chem. 2019 Oct 1;179:38-55. doi: 10.1016/j.ejmech.2019.06.037. Epub 2019 Jun 17. PubMed PMID: 31233921.

11: Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019 Aug;20(8):1083-1097. doi: 10.1016/S1470-2045(19)30274-8. Epub 2019 Jun 17. PubMed PMID: 31221619.

12: Affolter T, Llewellyn HP, Bartlett DW, Zong Q, Xia S, Torti V, Ji C. Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. PLoS One. 2019 May 21;14(5):e0217276. doi: 10.1371/journal.pone.0217276. eCollection 2019. PubMed PMID: 31112568; PubMed Central PMCID: PMC6528985.

13: Angeli A, Ferraroni M, Nocentini A, Selleri S, Gratteri P, Supuran CT, Carta F. Polypharmacology of epacadostat: a potent and selective inhibitor of the tumor associated carbonic anhydrases IX and XII. Chem Commun (Camb). 2019 May 14;55(40):5720-5723. doi: 10.1039/c8cc09568j. PubMed PMID: 31038135.

14: Zhang Y, Bowman K, Maleski J, Diamond S, Yeleswaram S. Effects of Epacadostat on Brain Extracellular Fluid Concentrations of Serotonin-an Intracerebral Microdialysis Study in Sprague-Dawley Rats. Drug Metab Dispos. 2019 Jul;47(7):710-714. doi: 10.1124/dmd.118.084053. Epub 2019 Apr 22. PubMed PMID: 31010933.

15: Poncelet L, Ait-Belkacem R, Marillier R, Gomes B, Stauber J. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model. J Pharm Biomed Anal. 2019 Jun 5;170:220-227. doi: 10.1016/j.jpba.2019.02.038. Epub 2019 Mar 22. PubMed PMID: 30933897.

16: Kwiatkowska D, Kluska P, Reich A. Beyond PD-1 Immunotherapy in Malignant Melanoma. Dermatol Ther (Heidelb). 2019 Jun;9(2):243-257. doi: 10.1007/s13555-019-0292-3. Epub 2019 Mar 29. Review. PubMed PMID: 30927248; PubMed Central PMCID: PMC6522569.

17: Li A, Barsoumian HB, Schoenhals JE, Caetano MS, Wang X, Menon H, Valdecanas DR, Niknam S, Younes AI, Cortez MA, Welsh JW. IDO1 Inhibition Overcomes Radiation-Induced "Rebound Immune Suppression" by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):903-912. doi: 10.1016/j.ijrobp.2019.03.022. Epub 2019 Mar 21. PubMed PMID: 30905636.

18: Gibney GT, Hamid O, Lutzky J, Olszanski AJ, Mitchell TC, Gajewski TF, Chmielowski B, Hanks BA, Zhao Y, Newton RC, Maleski J, Leopold L, Weber JS. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. J Immunother Cancer. 2019 Mar 20;7(1):80. doi: 10.1186/s40425-019-0562-8. PubMed PMID: 30894212; PubMed Central PMCID: PMC6425606.

19: Fu X, Yang Y, Xie J, Pan X, Yang X, Du Z, Hao E. Subcutaneous inoculation position affects the immune environment in CT26 carcinomas. Biochem Biophys Res Commun. 2019 Apr 30;512(2):244-249. doi: 10.1016/j.bbrc.2019.03.042. Epub 2019 Mar 14. PubMed PMID: 30879760.

20: Chen S, Song Z, Zhang A. Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions. Curr Top Med Chem. 2019;19(3):180-185. doi: 10.2174/1568026619666190308131805. Review. PubMed PMID: 30854972.